The safety profile characteristics of sunitinib were evaluated in patients who underwent nephrectomy for kidney cancer.
In this literature review, safety data were evaluated from phase III trials investigating sunitinib following nephrectomy, either in the more recent adjuvant setting after nephrectomy or in the metastatic setting, with a focus on new data from the CARMENA and SURTIME trials. In particular, the aim was to determine the specificity of toxicity in the adjuvant setting.
In the adjuvant setting, even if the toxicity profile of sunitinib does not differ significantly from that in the metastatic setting, the importance of the dose intensity and, thus, exposure has been emphasized. Consequently, as described mainly in the metastatic setting, management of the adverse effects of sunitinib remains critical.
Expert opinion on drug safety. 2020 Jun 10 [Epub ahead of print]
Luc Heraudet, Charlotte Domblides, Amaury Daste, Félix Lefort, Jean-Christophe Bernhard, Alain Ravaud, Marine Gross-Goupil
Department of Medical Oncology, Bordeaux University Hospital , Saint-André, France., Department of Urology, Bordeaux University Hospital , France.